Artificial intelligence is no longer a buzzword in the life sciences; rather, it is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms may ultimately control the industry’s future. Among the clinical-stage players quietly positioning themselves at the center of this shift is Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company that has spent years building a proprietary AI platform and is now turning that platform into something more ambitious than a drug-discovery tool.
The broader market context makes Oncotelic’s strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion, according to industry reports. This expansion underscores the increasing reliance on AI to streamline research and development, reduce costs, and accelerate the timeline from target identification to clinical trials.
Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts into its PDAOAI platform. This vast repository of biomedical knowledge enables the platform to identify novel drug targets, predict patient responses, and optimize therapeutic strategies with unprecedented speed and accuracy. By leveraging this data, Oncotelic aims to not only enhance its own pipeline but also to offer the platform as a service to other biotech and pharmaceutical companies, potentially creating a new revenue stream.
The implications of this announcement are profound. If Oncotelic can demonstrate that its AI-driven approach leads to successful clinical outcomes, it could validate the broader use of AI in drug development, encouraging more investment and partnerships. Moreover, the company’s ability to ingest and analyze massive datasets positions it as a key player in the competitive landscape, where data is the new currency. Investors should note that the latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC.
As the AI in drug-discovery market continues to expand, companies like Oncotelic that have invested early in proprietary AI infrastructure may have a significant advantage. The integration of 28 million abstracts is not just a technical achievement; it represents a strategic asset that could redefine how drugs are discovered and developed. For more information about the market dynamics and Oncotelic’s role, readers can visit the InvestorWire website at https://www.InvestorWire.com for comprehensive coverage and disclaimers.
